Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 459 of 3330
Next
>>
>
11451 to 11475 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MCF 10F	NM	-	Bosutinib	Src	nRTK	0.0064	uM	12254.145	1.0578	1.0639	1.7869
MCF 10F	NM	-	Bosutinib	Src	nRTK	0.032	uM	12254.145	1.0817	1.0899	1.7869
MCF 10F	NM	-	Bosutinib	Src	nRTK	0.16	uM	12254.145	1.0668	1.0737	1.7869
MCF 10F	NM	-	Bosutinib	Src	nRTK	0.8	uM	12254.145	0.7783	0.7383	1.7869
MCF 10F	NM	-	Bosutinib	Src	nRTK	4	uM	12254.145	0.4605	0.2959	1.7869
MCF 10F	NM	-	Bosutinib	Src	nRTK	20	uM	12254.145	0.3650	0.1378	1.7869
MCF 10F	NM	-	Bosutinib	Src	nRTK	100	uM	12254.145	0.3704	0.1473	1.7869
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.000256	uM	10817.145	0.9224	0.8989	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.00128	uM	10817.145	0.9183	0.8934	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.0064	uM	10817.145	0.9359	0.9166	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.032	uM	10817.145	0.9884	0.9851	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.16	uM	10817.145	0.9154	0.8896	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.8	uM	10817.145	0.6739	0.5520	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	4	uM	10817.145	0.2554	-0.1680	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	20	uM	10817.145	0.0846	-0.5908	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	100	uM	10817.145	0.1131	-0.5071	1.5564
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.0000853	uM	12365.17	0.9484	0.9543	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.000427	uM	12365.17	0.9124	0.9216	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.00213	uM	12365.17	0.9363	0.9434	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.0107	uM	12365.17	0.9232	0.9315	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.0533	uM	12365.17	0.9944	0.9951	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	0.267	uM	12365.17	0.9076	0.9172	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	1.33	uM	12365.17	0.5459	0.5359	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	6.67	uM	12365.17	0.0745	-0.3554	2.2930
MCF12A	NM	Basal B	Bosutinib	Src	nRTK	33.3	uM	12365.17	0.0628	-0.4017	2.2930

|<
<<
Previous
Page 459 of 3330
Next
>>
>
11451 to 11475 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)